NASDAQ:ARAVAravive Stock Price, Forecast & News

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARAV stock has increased by 112.4% and is now trading at $10.60. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive.

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aravive.

Aravive Inc (NASDAQ:ARAV) released its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.36. View Aravive's earnings history.

5 brokers have issued 12-month target prices for Aravive's shares. Their forecasts range from $15.00 to $31.00. On average, they expect Aravive's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 145.3% from the stock's current price. View analysts' price targets for Aravive.

News headlines about ARAV stock have trended somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aravive earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Aravive.

Aravive saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 264,400 shares, a decline of 21.8% from the June 15th total of 338,000 shares. Based on an average daily volume of 157,500 shares, the days-to-cover ratio is presently 1.7 days. Currently, 3.0% of the company's stock are sold short. View Aravive's Current Options Chain.

Some companies that are related to Aravive include Kadmon (KDMN), Homology Medicines (FIXX), Eagle Pharmaceuticals (EGRX), Provention Bio (PRVB), Cue Biopharma (CUE), Passage Bio (KROS), Vanda Pharmaceuticals (VNDA), Stemline Therapeutics (STML), Applied Therapeutics (APLT), RAPT Therapeutics (RAPT), Aprea Therapeutics (APRE), Radius Health (RDUS), Trillium Therapeutics (TRIL), Basilea Pharmaceutica (BPMUF) and Molecular Templates (MTEM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Applied Genetic Technologies (AGTC), Ardelyx (ARDX), Bank of America (BAC), Clovis Oncology (CLVS), Precision BioSciences (DTIL), Galmed Pharmaceuticals (GLMD), Inovio Pharmaceuticals (INO) and Myovant Sciences (MYOV).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAV stock can currently be purchased for approximately $10.60.

Aravive has a market capitalization of $169.60 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

The official website for Aravive is www.aravive.com.

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]